New federal mandates target the opaque financial arrangements between Pharmacy Benefit Managers and health plans to ensure service compensation remains reasonable under federal law. For decades, the “black box” of prescription drug pricing has frustrated employers who struggle to reconcile rising premiums with unclear benefit structures. By leveraging the authority of the Employee Benefit Security Administration, the Department of Labor is now demanding a level of granularity that was previously inaccessible to most plan fiduciaries. This shift is not merely a bureaucratic adjustment but a fundamental realignment of the power dynamics within the healthcare supply chain. Large corporations and self-insured entities have historically operated at a disadvantage, often signing contracts without knowing the exact profit margins of their vendors. The new requirements seek to close these informational gaps, compelling a degree of honesty that could redefine the economics of pharmacy benefits and ensure that every dollar spent is accounted for in a standardized manner.
Strengthening Fiduciary Oversight and Reporting Standards
Scope of New Reporting Requirements
The new regulations apply primarily to pharmacy benefit managers expecting to receive more than $1,000 for their services provided to self-insured plans governed by the Employee Retirement Income Security Act. Specifically, these mandates focus on larger plans with at least 100 participants, effectively exempting small to midsized employers with fully insured plans that fall outside the typical ERISA framework. This threshold ensures that the regulatory burden is concentrated on high-impact contracts where the potential for undisclosed financial gains is most significant. By requiring these entities to disclose their compensation structures before a service agreement is even executed, the Department of Labor is forcing transparency into the early stages of the procurement process. This proactive approach prevents hidden fees from being baked into the contract language, allowing fiduciaries to compare vendors on a level playing field. It also necessitates a more rigorous vetting process for health consultants.
Building on this structural foundation, the mandate requires a level of detail that covers both direct and indirect compensation. In the past, many PBMs utilized complex legal language to obscure the total amount of money they earned from a single plan. The new rules strip away these protections, requiring a clear breakdown of every fee, commission, and incentive payment associated with the contract. For plan fiduciaries, this data is not just a compliance requirement but a tool for fulfilling their legal duty to act in the best interest of plan participants. With the current focus on rising healthcare costs in 2026, having access to this information allows employers to defend their benefit choices against potential litigation or internal audits. By establishing these clear reporting boundaries, the federal government has created a environment where silence or ambiguity is no longer a viable business strategy for intermediaries, forcing a move toward more ethical and transparent service models.
Implementation Timelines and Periodic Disclosures
Service providers must prepare for these changes to take effect for plan years beginning on or after July 1, 2027. Once the regulations are active, PBMs will be held to a schedule of ongoing disclosures, providing updates every six months or even quarterly if a plan sponsor makes a specific request. This recurring requirement ensures that transparency is not a one-time event but a continuous obligation that evolves as market conditions and drug lists change. For years, the lack of real-time data has hindered the ability of health plans to react to price spikes or shifting rebate structures. Under the new rules, the frequency of reporting will allow for more agile decision-making, ensuring that compensation remains reasonable throughout the life of the contract. This cyclical reporting structure is designed to catch discrepancies as they arise, rather than years later during a forensic audit. It marks a significant departure from the traditional “set it and forget it” mentality.
Furthermore, the transition period between now and the mid-2027 start date provides a critical window for fiduciaries to update their internal governance protocols. Many organizations are already beginning to renegotiate contracts to include “transparency-first” clauses that mirror the upcoming federal standards. This anticipatory move helps avoid a chaotic transition when the rules formally take effect. The Department of Labor has signaled that it will provide additional guidance as the implementation date approaches, but the core requirements for timely and frequent reporting remain firm. By standardizing the disclosure timeline, the government is ensuring that all plans, regardless of their size or industry, receive the same level of financial clarity. This consistency is vital for creating a fair market where plan sponsors can accurately measure the value they receive for their healthcare spending. It also places a new emphasis on the role of the fiduciary as an active participant in the drug pricing ecosystem.
Addressing Spread Pricing and Rebate Aggregation
Unveiling Hidden Revenue Streams
A primary target of these transparency efforts is the practice of spread pricing, where a PBM charges a health plan a higher price for a drug than what it actually pays to the dispensing pharmacy. Historically, these margins were kept confidential, allowing intermediaries to capture substantial profits without the plan sponsor’s knowledge. The new rule mandates the disclosure of these spreads, alongside details regarding the flow of fees to third-party entities like rebate aggregators. By bringing these indirect compensation streams into the light, federal regulators are enabling health plans to conduct independent audits with much higher precision. These audits are crucial for satisfying the legal obligations under ERISA section 408(b)(2)(A), which requires fiduciaries to prove that their service arrangements are necessary and cost-effective. Without access to specific data on how money moves between manufacturers, managers, and pharmacies, fiduciaries have been left exposed to legal risks.
The inclusion of rebate aggregators in the disclosure mandate is particularly significant because these entities often operate in the background, collecting millions of dollars in incentives that are rarely shared with the employer. Under the new rules, every link in the financial chain must be documented, leaving no room for “lost” rebates or undisclosed administrative fees. This transparency allows plan sponsors to see exactly how much of their money is going toward actual healthcare versus administrative overhead. Moreover, it empowers fiduciaries to demand more favorable terms, as they can now point to specific data points during negotiations. This shift naturally leads to a more competitive marketplace where service providers must justify their costs through performance rather than through the manipulation of complex pricing models. By eliminating the ability to hide profit margins within the spread, the Department of Labor is directly addressing one of the most significant drivers of prescription drug inflation.
Future Mandates for Full Rebate Pass-Throughs
Looking ahead from 2026 toward the end of the decade, the regulatory landscape will become even more restrictive for intermediaries. Following the directives of the Consolidated Appropriations Act, PBMs will be required to pass through 100 percent of drug manufacturer rebates and discounts directly to group health plans for plan years starting on or after August 3, 2028. This move effectively eliminates the incentive for PBMs to favor higher-priced drugs that offer larger rebates, a practice that has long been criticized for inflating the total cost of care. Additionally, new amendments under ERISA section 726 will require retrospective disclosures, providing a historical look at drug spending and utilization patterns. These data points will serve as a benchmark for future negotiations, allowing plan sponsors to identify inefficiencies and demand better terms. The integration of these disclosures creates a comprehensive oversight mechanism.
This transition to a full pass-through model represents a complete transformation of the PBM business model, moving it from a profit-sharing intermediary to a fee-for-service administrator. By 2028, the financial incentives will be more closely aligned with the interests of the plan participants, as the focus shifts from maximizing rebate retention to minimizing the net cost of drugs. Employers should use the current period to evaluate their pharmacy benefit designs, ensuring they have the infrastructure to manage the 100 percent pass-through of these funds. This might involve setting up dedicated accounts or implementing new accounting practices to track rebate income. The retrospective reporting requirements will also force plan sponsors to take a more active role in analyzing their claims data. Rather than relying on summarized reports provided by the vendor, fiduciaries will have access to raw data that can be analyzed by third-party experts. This level of scrutiny was nearly impossible under the old system.
Strategic Oversight for Health Plan Fiduciaries
The Department of Labor’s initiative successfully established a framework where data-driven oversight replaced the previous reliance on vendor assurances. Fiduciaries moved beyond passive acceptance of contract terms and began utilizing their newly granted audit rights to scrutinize every dollar spent on prescription benefits. To capitalize on this shift, organizations should have already begun reviewing their current PBM contracts to ensure they are aligned with the upcoming 2027 disclosure deadlines. Investing in advanced data analytics will be essential for interpreting the complex disclosure reports that will soon become standard. By preparing for the 100 percent rebate pass-through requirements scheduled for 2028, plan sponsors can proactively restructure their benefit designs to maximize savings. The transition toward total transparency required a departure from traditional procurement habits, but it ultimately provided the empirical evidence needed to lower costs and improve the financial health of employee benefit plans across the country.
